Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus

Abstract Exosomes have been proposed as candidates for therapeutic immunization. The present study demonstrates that incorporation of the G protein of vesicular stomatitis virus (VSV-G) into exosome-like vesicles (ELVs) enhances their uptake and induces the maturation of dendritic cells. Targeting of VSV-G and ovalbumin as a model antigen to the same ELVs increased the cross-presentation of ovalbumin via an endosomal acidification mechanism. Immunization of mice with VSV-G and ovalbumin containing ELVs led to an increased IgG2a antibody response, expansion of antigen-specific CD8 T cells, strong in vivo CTL responses, and protection from challenge with ovalbumin expressing tumor cells. Thus, incorporation of VSV-G and targeting of antigens to ELVs are attractive strategies to improve exosomal vaccines.

[1]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[2]  R. Steinman,et al.  Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells , 1999, Current Biology.

[3]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[4]  L. Zitvogel,et al.  Dendritic cells or their exosomes are effective biotherapies of cancer. , 1999, European journal of cancer.

[5]  J. Slot,et al.  Proteomic and Biochemical Analyses of Human B Cell-derived Exosomes , 2003, The Journal of Biological Chemistry.

[6]  J. Yewdell,et al.  Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. , 1998, Journal of immunology.

[7]  A. Pichlmair,et al.  Tubulovesicular Structures within Vesicular Stomatitis Virus G Protein-Pseudotyped Lentiviral Vector Preparations Carry DNA and Stimulate Antiviral Responses via Toll-Like Receptor 9 , 2006, Journal of Virology.

[8]  L. Zitvogel,et al.  Prospects for exosomes in immunotherapy of cancer , 2006, Journal of cellular and molecular medicine.

[9]  A. Sher,et al.  CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. , 2000, Immunity.

[10]  R. Medzhitov,et al.  Regulation of Phagosome Maturation by Signals from Toll-Like Receptors , 2004, Science.

[11]  M. Whitt,et al.  A fusion-defective mutant of the vesicular stomatitis virus glycoprotein , 1990, Journal of virology.

[12]  J. Lifson,et al.  MHC-I–restricted presentation of HIV-1 virion antigens without viral replication , 2001, Nature Medicine.

[13]  L. Zitvogel,et al.  Dendritic cell-derived exosomes as cell-free peptide-based vaccines. , 2005, Critical reviews in immunology.

[14]  K. Überla,et al.  Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses , 2004, The journal of gene medicine.

[15]  A. Helenius,et al.  Pathway of vesicular stomatitis virus entry leading to infection. , 1982, Journal of molecular biology.

[16]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection 1 , 2004, The Journal of Immunology.

[17]  J. Yewdell,et al.  Multiple Antigen-Specific Processing Pathways for Activating Naive CD8+ T Cells In Vivo , 2001, The Journal of Immunology.

[18]  M. Graf,et al.  Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. , 2000, Human gene therapy.

[19]  I. Jones,et al.  Non-polar distribution of green fluorescent protein on the surface of Autographa californica nucleopolyhedrovirus using a heterologous membrane anchor. , 2002, Journal of biotechnology.

[20]  Scott N. Mueller,et al.  Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus 11 , 2002, The Journal of Immunology.

[21]  M. Kovacsovics-Bankowski,et al.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.

[22]  K. Überla,et al.  Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps , 2007, Virology Journal.

[23]  Zhengfan Jiang,et al.  Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. , 2007, Virology.

[24]  R. Steinman,et al.  Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. , 2006, Virology.

[25]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[26]  Xuetao Cao,et al.  Efficient induction of antitumor T cell immunity by exosomes derived from heat‐shocked lymphoma cells , 2006, European journal of immunology.

[27]  L. Zitvogel,et al.  Tumor-derived exosomes: a new source of tumor rejection antigens. , 2002, Vaccine.

[28]  Sebastian Amigorena,et al.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells , 1999, Nature Cell Biology.

[29]  J. Miller,et al.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system , 1987, Molecular and cellular biology.

[30]  O. Schwartz,et al.  Enhanced Presentation of Major Histocompatibility Complex Class I-Restricted Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Specific Epitopes after DNA Immunization with Vectors Coding for Vesicular Stomatitis Virus Glycoprotein- Pseudotyped HIV-1 Gag Particles , 2002, Journal of Virology.

[31]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[32]  K. Überla,et al.  Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies , 2007, Virology.